Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough - Full Text View

Purpose

Chronic cough is defined by its persistence beyond 8 weeks. Many conditions can explain the existence of a bronchial inflammation. In the management of chronic cough, the search for bronchial hyperreactivity (HRB) is recommended. The treatment relies primarily on the prescription of inhaled corticosteroids. It has been shown recently that the existence of an HRB with Methacholine (bronchial provocation test used in routine) does predict the effectiveness of inhaled corticosteroid treatment in no more than 50% of cases.

It is now possible to assess the bronchial inflammation by rapid, non-invasive and reproducible tests such that the fraction of exhaled nitric oxide (FeNO) and bronchial provocation test with mannitol. In a retrospective study, it was shown that an increased value of FeNO (cut-off > 35 ppb) predicts a positive response to treatment with a sensitivity of 90% and a specificity of 80%.

Condition	Intervention
Cough Bronchial Hyperreactivity	Procedure: bronchial provocation test with mannitol


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	Measurement of Exhaled NO and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough

Resource links provided by NLM:

MedlinePlus related topics: Cough Steroids

Drug Information available for: Mannitol

U.S. FDA Resources

Further study details as provided by Centre Hospitalier Universitaire de Saint Etienne:

Primary Outcome Measures:

The intensity of coughing on a 10-cm visual scale [ Time Frame: 6 weeks after treatment with inhaled corticosteroids ]

Secondary Outcome Measures:

Sensitivity, specificity, positive predictive value and negative predictive value of the threshold value of 35 ppb FeNo to the clinical response seen as positive if the EVA reduces cough of at least 2 cm [ Time Frame: 6 weeks after treatment with inhaled corticosteroids ]
Sensitivity, specificity, positive predictive value and negative predictive value of response to bronchial provocation test with mannitol on the clinical response seen as positive if the EVA reduces cough of at least 2 cm [ Time Frame: 6 weeks after treatment with inhaled corticosteroids ]
Correlation between the value of FeNo and dose of mannitol causing a fall of 15% of maximum volume expired second (PD15) [ Time Frame: 6 weeks after treatment with inhaled corticosteroids ]
Score quality of life of the Leicester Cough Questionnaire [ Time Frame: 6 weeks after treatment with inhaled corticosteroids ]


Enrollment:	30
Study Start Date:	November 2008
Study Completion Date:	September 2010
Primary Completion Date:	September 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: bronchial provocation test with mannitol Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale. After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests.	Procedure: bronchial provocation test with mannitol Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device. Apply nose clip and subject should be directed to breathe through the mouth Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules) The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1) Insert 5 mg capsule into inhalation device, and proceed as above Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered. Other Name: Aridol

Arms

Assigned Interventions

Experimental: bronchial provocation test with mannitol

Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.

After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests.

Procedure: bronchial provocation test with mannitol

Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.

Apply nose clip and subject should be directed to breathe through the mouth
Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)
The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration
At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip
At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)
Insert 5 mg capsule into inhalation device, and proceed as above
Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered.

Other Name: Aridol

Detailed Description:

The purpose of this study is to show that the use of the prospective value of exhaled NO can predict response to treatment with inhaled corticosteroids in adult with chronic cough. In addition we will assess the interest of the prognosis of bronchial provocation test with mannitol in this indication.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic Cough during 2 months
Social Security regimen affiliated
Consent form signed

Exclusion Criteria:

Smoking active
Treatment with angiotensin converting enzyme inhibitor
Clinical signs of obvious gastroesophageal reflux
Clinical rhinosinusitis
Recent respiratory infection (< 1 month)
Corticosteroid Treatment(oral or inhaled) within 2 weeks
VEMS < 1 L or < 80% of the theoretical value
Existence of an obstructive ventilatory disorder defined as a report (FEV/FVC) < 90% of the theoretical value

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00916526

Locations


France
CHU de Saint-Etienne
Saint-Etienne, France, 42055

Sponsors and Collaborators

Centre Hospitalier Universitaire de Saint Etienne

Pharmaxis

Investigators


Principal Investigator:	Frédéric COSTES, MD PhD	CHU de Saint-Etienne

More Information


Responsible Party:	Clément Caillaux, CHU de Saint-Etienne
ClinicalTrials.gov Identifier:	NCT00916526 History of Changes
Other Study ID Numbers:	0808078 2008-A00846-49 ( Other Identifier: AFSSAPS )
Study First Received:	June 8, 2009
Last Updated:	November 23, 2010

Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:


Chronic cough Inhaled corticosteroid treatment Bronchial provocation test with mannitol Methacholine

Additional relevant MeSH terms:


Cough Bronchial Hyperreactivity Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms	Bronchial Diseases Mannitol Diuretics, Osmotic Diuretics Natriuretic Agents Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 22, 2017

Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough (MANOTOUX)